Two-Year Outcomes Of Preserflo Microshunt Implantation At A Regional Nhs Ophthalmic Centre In The Uk
Published 2025 - 43rd Congress of the ESCRS
Reference: PP24.01 | Type: Poster | DOI: 10.82333/wvf7-8s68
Authors: Ettore Melardi* 1 , Valence Jordan 1 , Melissa Chin 1 , Jennifer Kirkby 1 , Azeem Siddique 1 , Asifa Shaikh 1
1Ophthalmology,Buckinghamshire NHS Healthcare Trust,Aylesbury,United Kingdom
Purpose
To determine the post-operative outcomes of Preserflo Microshunt implantation in patients with glaucoma including intraocular pressure reduction, progression, and complications.
Setting
A regional NHS ophthalmic centre in the United Kingdom.
Methods
This was a retrospective study of Preserflo Microshunt implantation between May 2022 and February 2025. A review of electronic medical records was carried out to obtain demographics, intraocular pressure, visual field and optical coherence tomography data, and number of glaucoma medications at baseline and multiple post-operative timepoints (3 months, 6 months, 12 months, 24 months). Intra-operative and post-operative complications were also recorded. The data was analysed using the paired t-test to determine whether there were significant changes in intraocular pressure and medications postoperatively, and whether there was glaucoma progression in the cohort during the study period.
Results
Thirteen eyes of 12 patients completed 24 months follow up. Mean age was 78.85±4.91 years and 69.23% had POAG. Baseline IOP and mean deviation (MD) were 18.46±5.04 mmHg and -11.95 dB, respectively, and mean glaucoma agents was 2.61.
Twenty-four months post-operatively, mean IOP was 13.61±4.31, with a 26.27% mean reduction (p=0.035). Nine eyes (69.23%) were medication-free. No significant change in MD (p=0.294) or RNFL thickness (p=0.076) was noted.
Most complications were confined to the early post-operative period: hyphaema (2), choroidal effusions (1), hypotony (1), choroidal folds (1) and macular folds (1).
One patient required surgical revision and developed aqueous misdirection at 2 years. One patient failed within the first year.
Conclusions
Preserflo Microshunt implantation resulted in a 26.27% decrease in intraocular pressure which was sustained 24 months after surgery. Notably, most patients maintained adequate pressure control with no glaucoma medication on last follow-up. A trend towards glaucoma progression and increased ocular pressure and glaucoma medication was noticed compared to 1-year results.